Patent Awarded to Medafor, Inc., for Topically Applied Blood Clotting Methods
Exclusive U.S. Protection Granted for Microparticle Hemostatic Technology

Minneapolis, Minn., May 2000 - Recognizing the distinctive qualities of Medafor's innovative technology, the U.S. Patent Office has issued protection covering 31 method claims for producing hemostasis using microporous particles. The Medafor technology patent was issued this month, approving an application filed by the company in February of 1999.

The primary claim of Patent No. 6,060,461 is as follows:

"A method for enhancing the formation of clots on a wound where blood is present, comprising the steps of applying porous particles having average diameter dimensions of .5 to 1000 microns, and allowing said porous particles to remain in contact with blood while clotting initiates. Said porous particles have molecular sieve cutoff values between 5,000 and 200,000 Daltons."

"We feel that the need to address the management of profuse bleeding in trauma, surgical and treatment situations has been acknowledged, and that the unique capabilities of Medafor's technology to address this need have been recognized," stated Dr. James Drake, Medafor's Chief Scientist and the holder of the new patent. "The patent's broad coverage will be a benefit to patients and healthcare providers, as well as to the company and its investors."

Richard Zerban, Medafor's CEO, added, "We're proud of the breadth of the patent and the speed of its issuance. Securing and retaining the exclusive rights to technology developments is critical to our value and growth. We plan to build on this patent through the protection of new products and delivery systems, creating an inventory of highly protected intellectual property."

Safety and efficacy testing of Medafor's hemostatic technology is currently under way. The company plans to submit for governmental clearances (FDA in the U.S.; CE in Europe) in the fourth quarter of 2001.

Medafor, Inc., is a privately held Minnesota corporation, founded in 1999 to develop and market groundbreaking hemostatic technology based on engineered biopolymeric microporous particles.

Statements made in this release have not been evaluated by the FDA or any other regulating body, and Medafor's products are not currently available for use in humans. This release may contain forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate, or unforeseen risks or circumstances materialize, actual results could vary materially from expectations and projections stated herein. The company assumes no obligation to update any forward-looking statements as a result of new information or future developments. BACK.